LBL-007 is a fully human monoclonal antibody against lymphocyte activation gene-3 (LAG-3).LAG-3 is an immune checkpoint receptor expressed on activated T cells, which negatively regulates these activated T cells and leads to tumor immune escape.In preclinical studies, LBL-007 can specifically bind to human LAG-3, stimulate the release of IL-2, block the combination of LAG-3 with MHC Ⅱ and other ligands, and significantly inhibit tumor growth.On August 13, 2019 and March 27, 2020, the NMPA and FDA clinical approval documents were obtained respectively.At present, LBL-007 has completed phase I clinical research on single-drug tolerance, safety, pharmacokinetics and preliminary efficacy in China.At the same time, the phase I/II clinical study of LBL-007 combined with toripalimab in the treatment of advanced malignant tumors is underway, and the latest results of the clinical study of the combined treatment of advanced melanoma have been announced during the ASCO meeting in 2022, showing impressive results. Encouraging efficacy signals and safety advantages.
On December 13, 2021, our company formally reached an authorization and cooperation agreement with BeiGene, granting BeiGene a global R&D and production license for LBL-007, as well as exclusive commercialization rights outside of China.At present, our company is cooperating with BeiGene to carry out global clinical development. The combination of LBL-007 and tislelizumab (anti-PD-1 monoclonal antibody, trade name: Tislelizlezlezlezlene®) has multiple clinical trials in the treatment of malignant tumors. The study is in phase Ib/II stage.

LBL-015 is an anti-programmed death receptor-1 (PD-1) antibody-transforming growth factor beta receptor 2 (TGF-βR2) bifunctional antibody fusion protein.LBL-015 can simultaneously block PD-1/PD-L1 and TGF-β/TGF-βR2 signaling pathways, improve immunosuppression, and enhance immune response.In addition, LBL-015 can block TGF-β in the tumor microenvironment, further improving immune cell response and inhibiting tumor metastasis.On February 8, 2021 and July 1, 2021, the FDA and NMPA clinical approval documents were obtained respectively.Currently, LBL-015 single-drug clinical research is in phase I/II phase.The indications for LBL-015 to be developed include hematological tumors and solid tumors.
Weilizhibo owns all the rights of LBL-015 worldwide.

LBL-019 is a monoclonal antibody targeting tumor necrosis factor receptor-2 (TNFR2).LBL-019 can specifically bind to TNFR2, block the combination of TNFR2 and TNFα, and enhance the activity of immune cells through immune regulation to achieve anti-tumor effects.On December 10, 2021 and December 17, 2021, the NMPA and FDA clinical approval documents were obtained respectively.Currently, LBL-019 single-drug clinical research is in phase I/II phase.LBL-019 is intended to be developed for indications including hematological tumors and solid tumors.
Weilizhibo owns all the rights of LBL-019 worldwide.

The LBL-033 project has obtained NMPA and FDA clinical trial approval documents on February 16, 2023 and June 12, 2023, respectively.Currently, LBL-033 single-drug clinical research is in phase I/II phase.LBL-033 is intended to be developed for a variety of solid tumors such as ovarian cancer.
Weilizhibo owns all the rights of LBL-033 worldwide.

LBL-024 is a bispecific antibody consisting of anti-programmed death-ligand-1 (PD-L1) and anti-4-1BB (CD137) antibodies.LBL-024 blocks the immunosuppressive pathway by targeting PD-L1, and effectively gathers and activates 4-1BB to play an important co-stimulatory role, thereby activating T cells to exert a strong immune effect and achieve the purpose of anti-tumor.The LBL-024 project was approved by the FDA and NMPA for clinical approval on July 30, 2021 and September 9, 2021, respectively.Currently, LBL-024 single-drug clinical research is in phase I/II phase.LBL-024 is intended to be developed for indications including hematological tumors and solid tumors.
Weilizhibo owns all rights of LBL-024 worldwide.